Back to homepageConvinced by the new therapeutic era represented by microbiota, Smaltis has been involved for over ten years in the study of roles played by microorganisms in health and well-being. With its innovative models and the acquisition of expertise in designing tailor-made experiments, Smaltis is committed to providing you with its expertise in the field, actively collaborating with you to accelerate the development of your prophylactic or therapeutic health products that target a microbiota.
Enhance the value of your products by entrusting them to a qualified laboratory
Whether your products are derived from microorganisms and/or act on a specific microbiota, optimize and streamline their development by entrusting them to our laboratories.
Smaltis actively supports the development of microorganisms and related products, such as:
- Live Biotherapeutic Products (LBP)
- Probiotics
- Postbiotics
- Synbiotics…
Our services also support projects based on other active compounds, which may include:
- Prebiotics
- Extracts
- Drug candidates…
A global approach dedicated to your developments
From screening stages to clinical studies
| DEVELOPMENT STAGES |
1
RESEARCH AND SELECTION |
2
PROOF OF CONCEPT / EFFICACY |
3
BIOPROCESSES |
4
(PRE)CLINICAL |
| YOUR NEEDS |
Strain screening, |
Search for health benefits, |
Optimization of the bioproduction process, |
Verification of the (pre)clinical impact of candidates, |
| OUR SOLUTIONS |
Functional and safety characterization of strains, |
Study of flora modulation, |
Optimization of culture conditions, |
Analysis of clinical samples & Metagenomic studies, |
Our promise: commitment and reliability to facilitate and accelerate your developments
The therapeutic potential revealed through the exploration of microbiota requires science and rigor, values on which Smaltis is uncompromising. The researchers at Smaltis accompany you with their expertise, dedicated equipment, and reliable partners to successfully execute your projects with the precision and flexibility unique to each study. From the development stages to data interpretation, we work hand in hand with your teams to achieve robust and clear results you can rely on.
From the design of manipulations to data interpretation, the project is carried out in partnership with your teams, ensuring complete transparency in terms of results and experiment progress. The goal is to find the best solution for your projects, applying the scientific rigor they require.
For each project, Smaltis commits to deploying all its efforts to finding solutions tailored to your challenges and that overcome the inherent obstacles in manipulating microorganisms. Perseverance pays off, a saying that we live up to!
Smaltis collaborates with experts to provide complementary solutions, addressing all your various needs. The team benefits, for example, from a strategic partnership with RD-Biotech, specialized in the biomanufacturing of plasmids and antibodies.
Smaltis is a member of networks working on microbiome-related themes, such as the Programming Committee of the Polepharma Microbiomics Days, to stay closely attuned to the developments and needs of this sector, the challenges you face, and the solutions to be provided.
Smaltis has the necessary equipment and tools for culturing even the most demanding microorganisms, be it bacteria, yeast, or molds. Smaltis has demonstrated its capabilities with a wide range of species and strains. The laboratory is equipped, among other things, with an anaerobic station that allows for precise regulation of growth atmospheres.
Pierre BELICHARD
CEO
ENTEROME
As part of the development of our candidate EB8018 designed to block bacteria expressing virulence factor FimH (a key inducer of the inflammatory cascade of the intestine, particularly in patients with Crohn disease), we have successively called upon the services of SMALTIS. In the preclinical phase, they first quantified in vitro the adhesion and invasion capacities of a collection of strains isolated from patients on a model of intestinal cell infection and then evaluated the impact of our molecule on these strains. The quality of the work performed, the level of expertise of the team combined with the ability to listen and adapt, led us to include SMALTIS as a service provider in our Phase 1b clinical study. The team developed a customized procedure to isolate and dissociate bacteria called "adherent" and "invasive" in intestinal biopsies, and then demonstrated the action of our EB8018 compound on these strains. SMALTIS continues to support the development of EB8018 in a phase 2a clinical trial.
Romain DAILLERE
Head of Preclinical Research - Co-founder
EVERIMMUNE
As part of the Oncobax®-AK project and the development of Live Biotherapeutic Products to potentiate the efficacy of cancer immunotherapies, we called upon Smaltis' services to characterize one of our candidate bacterial strains. The objective was to provide a complete file to the regulatory authorities regarding the characteristics of the strain, before initiating clinical studies. The Smaltis team worked hard to develop the protocols and test conditions necessary to determine the specificities of the strain of interest. The rigor shown by Smaltis' researchers, the quality and detail of the data transmitted, as well as the scientific relevance of the various characterization tests, allowed us to meet the regulatory requirements and to initiate the clinical trials with confidence. We are delighted to have collaborated with Smaltis.
Caroline GEBUS
Bioprocess Scientist
OM Pharma
We use Escherichia coli strains to manufacture our Uro-Vaxom® product for the prevention of recurrent lower urinary tract infections and co-treatment of acute urinary tract infections and, in accordance with regulatory requirements, we must demonstrate the stability of our strains. We therefore asked SMALTIS to develop a tailor-made quality control method. In addition to their ability to listen to customer needs and propose new ideas, the SMALTIS team has also distinguished itself by the quality and accuracy of its analysis reports. At present, the partnership established with SMALTIS is a real asset for OM Pharma.
Sophie MAC-MARY
CEO
SKINEXIGENCE
Smaltis is a laboratory that set up in the same building as our company, Skinexigence, from its inception. The proximity of our offices and the identification of a very interesting collaboration opportunity allowed us to quickly initiate a partnership to meet the growing demand from our clients for studies on the skin microbiota of volunteers. Specialized in the evaluation of the effectiveness of dermo-cosmetic products, it was only natural that we turned to Smaltis to provide our clients with expertise in the study of skin flora. For these studies, Smaltis performs skin sampling on our volunteers, sample preparation, and metagenomic analyses. The development of a very rigorous and calibrated protocol enables them to access relevant and reliable information regarding the evolution or not of the skin microbiota of a subject, in relation to the clinical parameters we observe.
Nicolas COULIN
Laboratory Manager
SOLICAZ
Solicaz develops natural bacterial biostimulation solutions to meet the challenges of agro-ecological transition and climate change. These PGPG (Plant Growth Promoting Rhizobacteria) bacteria provide benefits for improving plant growth and resistance. In order to exploit their full potential, we needed to call on a molecular biology expert to robustly determine the identity of a pool of selected strains. We identified Smaltis, who fully met our expectations by providing comprehensive expertise. The laboratory proved to be a true partner of choice, with whom we worked jointly to identify and test the method best suited to our needs. Their flexibility and commitment ensure that we have reliable results, and despite the geographical distance that separates us, our various subsidiaries will continue to work with Smaltis.